Cargando…

Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study

The progression of cognitive decline is heterogeneous in the three most common idiopathic parkinsonian diseases: Parkinson disease, multiple system atrophy and progressive supranuclear palsy. The causes for this heterogeneity are not fully understood, and there are no validated biomarkers that can a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bäckström, David, Granåsen, Gabriel, Mo, Susanna Jakobson, Riklund, Katrine, Trupp, Miles, Zetterberg, Henrik, Blennow, Kaj, Forsgren, Lars, Domellöf, Magdalena Eriksson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947320/ https://www.ncbi.nlm.nih.gov/pubmed/35350553 http://dx.doi.org/10.1093/braincomms/fcac040

Ejemplares similares

Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study
por: Bäckström, David, et al.
Publicado: (2018)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

Polymorphisms in dopamine‐associated genes and cognitive decline in Parkinson's disease
por: Bäckström, D., et al.
Publicado: (2017)

Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study
por: Jakobson Mo, Susanna, et al.
Publicado: (2013)

The Effects of Working Memory Updating Training in Parkinson’s Disease: A Feasibility and Single-Subject Study on Cognition, Movement and Functional Brain Response
por: Walton, Lois, et al.
Publicado: (2021)

Evaluating a frontostriatal working-memory updating-training paradigm in Parkinson’s disease: the iPARK trial, a double-blinded randomized controlled trial
por: Domellöf, Magdalena Eriksson, et al.
Publicado: (2020)

Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders
por: Zhu, Shaochun, et al.
Publicado: (2022)

Plasma Metabolite Markers of Parkinson’s Disease and Atypical Parkinsonism
por: Pathan, Meerakhan, et al.
Publicado: (2021)

Validation of dynamic [(18)F]FE-PE2I PET for estimation of relative regional cerebral blood flow: a comparison with [(15)O]H(2)O PET
por: Jakobson Mo, Susanna, et al.
Publicado: (2022)

Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment
por: Ekman, Urban, et al.
Publicado: (2014)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT—a clinical comparison
por: Jakobson Mo, Susanna, et al.
Publicado: (2018)

Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism
por: Degerman, Sofie, et al.
Publicado: (2014)

Distinct cortical and subcortical predictors of Purdue Pegboard decline in Parkinson’s disease and atypical parkinsonism
por: Wilkes, Bradley J., et al.
Publicado: (2023)

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease
por: Maple-Grødem, Jodi, et al.
Publicado: (2021)

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
por: Hall, Sara, et al.
Publicado: (2018)

Increased CSF biomarkers of angiogenesis in Parkinson disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Impaired synaptic function is linked to cognition in Parkinson's disease
por: Selnes, Per, et al.
Publicado: (2017)

GBA and APOE Impact Cognitive Decline in Parkinson’s Disease: A 10-Year Population-Based Study
por: Szwedo, Aleksandra A., et al.
Publicado: (2022)

Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study
por: Walton, Lois, et al.
Publicado: (2022)

Atypical parkinsonism: an update
por: Stamelou, Maria, et al.
Publicado: (2013)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Orthostatic Hypotension in Patients with Parkinson's Disease and Atypical Parkinsonism
por: Fereshtehnejad, Seyed-Mohammad, et al.
Publicado: (2014)

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
por: Santaella, Anna, et al.
Publicado: (2020)

Retinal Structure Abnormalities in Parkinson’s Disease and Atypical Parkinsonism
por: Ma, Xinxin, et al.
Publicado: (2023)

Synergistic Association between Plasma Aβ(1–42) and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia
por: Chiu, Ming-Jang, et al.
Publicado: (2021)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease
por: von Otter, Malin, et al.
Publicado: (2010)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Atypical Ubiquitination and Parkinson’s Disease
por: Buneeva, Olga, et al.
Publicado: (2022)

Molecular Imaging of the GABAergic System in Parkinson’s Disease and Atypical Parkinsonisms
por: Terkelsen, Miriam H., et al.
Publicado: (2022)

Parkinson’s disease with restless legs syndrome—an in vivo corneal confocal microscopy study
por: Andréasson, Mattias, et al.
Publicado: (2021)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pmnq13l01bag0eha366e36eu0k